Medical Oncology

, 34:66 | Cite as

Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients

  • Yuki Osada
  • Hideki Arakaki
  • Satoshi Takanashi
  • Chisako Ito
  • Yoshinobu Aisa
  • Tomonori NakazatoEmail author
Letter to the Editor

Dear Editor,

Treatment with tyrosine kinase inhibitors (TKIs) dramatically improved the survival of patients with chronic myeloid leukemia (CML). However, cardiovascular diseases (CVD) were retrospectively reported in patients with baseline CVD risk factors during TKI treatment [ 1, 2, 3]. We estimated the risk of developing CVD in patients treated with TKI by retrospectively applying the Systematic Coronary Risk Evaluation (SCORE) chart proposed by the European Society of Cardiology (ESC) and evaluating the risk factors at baseline. It has been reported that SCORE chart evaluation at disease baseline could be a valid tool to identify patients at high risk of atherosclerotic events during nilotinib treatment [ 4, 5, 6]. We applied the “low-risk” SCORE chart because the prevalence of CVD in the Japanese population is lower than that in Western populations. We enrolled 40 CML-CP patients treated with TKI as the first-line treatment. The median follow-up duration was 52 months. The...


Chronic Kidney Disease Imatinib Chronic Myeloid Leukemia Dasatinib Nilotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No specific funding was obtained to support the conduct of this study.

Compliance with ethical standards

Conflict of interest

All authors have no potential conflicts of interest to report.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.


  1. 1.
    Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival. A systematic review and meta-analysis. JAMA Oncol. 2016;. doi: 10.1001/jamaoncol.2015.5932.Google Scholar
  2. 2.
    Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia. A population-based cohort study. Ann Intern Med. 2016;165(3):161–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Aichberger KJ, Herndihofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Breccia M, Colafigli G, Molica M, et al. Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib. Am J Hematol. 2015;90(5):E100–1.CrossRefPubMedGoogle Scholar
  5. 5.
    Breccia M, Molica M, Zacheo I, et al. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular disease during nilotinib treatment. Ann Hematol. 2015;94:393–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Rea D, Mirault T, Raffoux E, et al. Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. Leukemia. 2015;29:1206–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suita study. J Atheroscler Thromb. 2014;21:784–98.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Yuki Osada
    • 1
  • Hideki Arakaki
    • 1
  • Satoshi Takanashi
    • 1
  • Chisako Ito
    • 1
  • Yoshinobu Aisa
    • 1
  • Tomonori Nakazato
    • 1
    Email author
  1. 1.Department of HematologyYokohama Municipal Citizen’s HospitalYokohamaJapan

Personalised recommendations